Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2018

Open Access 01-12-2018 | Research

Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology

Authors: Michael Malek-Ahmadi, Kewei Chen, Sylvia E. Perez, Anna He, Elliott J. Mufson

Published in: Alzheimer's Research & Therapy | Issue 1/2018

Login to get access

Abstract

Background

Cognitive composite scores are used as the primary outcome measures for Alzheimer’s disease (AD) prevention trials; however, the extent to which these composite measures correlate with AD pathology has not been fully investigated. Since many on-going AD prevention studies are testing therapies that target either amyloid or tau, we sought to establish an association between a cognitive composite score and the underlying pathology of AD.

Methods

Data from 192 older deceased and autopsied persons from the Rush Religious Order Study were used in this study. All participants were classified at their initial evaluations with a clinical diagnosis of no cognitive impairment (NCI). Of these individuals, 105 remained NCI at the time of their death while the remaining 87 progressed to mild cognitive impairment (MCI) or AD. A cognitive composite score composed of eight cognitive tests was used as the outcome measure. Individuals were classified into groups based on Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropathological diagnosis and Braak stage.

Results

The rate of annualized composite score decline was significantly greater for the high CERAD (p < 0.001, d = 0.56) and Braak (p < 0.001, d = 0.55) groups compared with the low CERAD and Braak groups, respectively. Mixed-model repeated measure (MMRM) analyses revealed a significantly greater difference in composite score change from baseline for the high CERAD group relative to the low CERAD group after 5 years (Δ = −2.74, 95% confidence interval (CI) −5.01 to −0.47; p = 0.02). A similar analysis between low and high Braak stage groups found no significant difference in change from baseline (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56).

Conclusions

These data provide evidence that decreased cognitive composite scores were significantly associated with increased AD pathology and provide support for the use of cognitive composite scores in AD prevention trials.
Literature
1.
Reiman EM, Langbaum JBS, Tariot PN. Alzheimer’s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010;4:3–14.CrossRefPubMed
2.
Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;19:228fs13.CrossRef
3.
Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH. Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010;6:257–64.CrossRefPubMedPubMedCentral
4.
5.
Schneider LS, Mangialasche M, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251–83.CrossRefPubMedPubMedCentral
6.
Hendrix SB. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res Ther. 2012;4:24.CrossRefPubMedPubMedCentral
7.
Lopez OL, Becker JT, Chang Y-F, Sweet RA, DeKosky ST, Gach MH, Carmichael OT, McDade E, Kuller LH. Incidence of mild cognitive impairment in the Pittsburgh cardiovascular health study-cognition study. Neurology. 2012;79:1599–606.CrossRefPubMedPubMedCentral
8.
Chen Y, Denny KG, Harvey D, Farias ST, Mungas D, DeCarli C, Beckett L. Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based elderly cohort. Alzheimers Dement. 2017;13(4):399–405.CrossRefPubMed
9.
10.
11.
Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer’s disease. N Engl J Med. 2013;368:1169–71.CrossRefPubMed
12.
Langbaum JBS, Hendrix SB, Ayutyetnot N, Chen K, Fleisher AS, Shar RC, Bennett DA, Tariot PN, Reiman EM. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:666–74.CrossRefPubMedPubMedCentral
13.
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS, Australian Imaging, Biomarkers, and lifestyle flagship study of ageing, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s disease cooperative study. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961–70.CrossRefPubMedPubMedCentral
14.
Coley N, Gallini A, Ousset PJ, Vellas B, Andrieu S, GuidAge study group. Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. Alzheimers Dement. 2016;12(12):1216–25.CrossRefPubMed
15.
Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, O'Brien RJ, Selnes OA, Albert MS, BIOCARD Research Team. Hypothetical preclinical Alzheimer’s disease groups and longitudinal cognitive change. JAMA Neurol. 2016;73(6):698–705.CrossRefPubMedPubMedCentral
16.
Hassenstab J, Monsell SE, Mock C, Roe CM, Caims NJ, Morris JC, Kukull W. Neuropsychological markers of cognitive decline in persons with Alzheimer disease neuropathology. J Neuropathol Exp Neurol. 2015;74(11):1086–92.CrossRefPubMed
17.
Jutten RJ, Harrison J, de Jong FJ, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in cognition study. Alzheimers Dement (NY). 2017;3(1):130–8.
18.
Ritchie K, Ropacki M, Albala B, Harrison J, Kaye J, Kramer J, Randolph C, Ritchie CW. Recommended cognitive outcomes in preclinical Alzheimer's disease: consensus statement from the European prevention of Alzheimer's dementia project. Alzheimers Dement. 2017;13(2):186–95.CrossRefPubMed
19.
Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA. Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci. 2013;5:50.CrossRefPubMedPubMedCentral
20.
Riley KP, Jicha GA, Davis D, Abner EL, Cooper GE, Stiles N, Smith CD, Kryscio RJ, Nelson PT, Van Eldik LJ, Schmitt FA. Prediction of preclinical Alzheimer’s disease: longitudinal rates of change in cognition. J Alzheimers Dis. 2011;25:707–17.CrossRefPubMedPubMedCentral
21.
Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, Kukull W. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2014;83:434–40.CrossRefPubMedPubMedCentral
22.
Malek-Ahmadi M, Lu S, Chan Y, Perez SE, Chen K, Mufson EJ. Cognitive domain dispersion association with Alzheimer’s pathology. J Alzheimers Dis. 2017;58(2):575–83.CrossRefPubMedPubMedCentral
23.
24.
Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158(2):469–90.CrossRefPubMed
25.
Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The rush memory and aging project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25:163–75.CrossRefPubMed
26.
Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, Fox JH, Cochran EJ, Arends D, Treinkman AD, Wilson RS. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27(3):169–76.CrossRefPubMed
27.
Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378–184.CrossRefPubMed
28.
Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691–701.CrossRefPubMedPubMedCentral
29.
Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging. 1997;18:S91–4.CrossRefPubMed
30.
Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed
31.
The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging. 1997;18:S1–2.CrossRef
32.
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–204.CrossRefPubMed
33.
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.CrossRefPubMed
34.
Jellinger KA. A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. Biochim Biophys Acta. 2009;1792(7):730–40.CrossRefPubMed
35.
Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205.CrossRefPubMed
36.
Mitchell TW, Nissanov J, Han LY, Mufson EJ, Schneider JA, Cochran EJ, Bennett DA, Lee VM, Trojanowski JQ, Arnold SE. Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem. 2000;48:1627–38.CrossRefPubMed
37.
38.
39.
Gold G, Bouras C, Kövari E, Canuto A, Glaría BG, Malky A, Hof PR, Michel JP, Giannakopoulos P. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol. 2000;99(5):579–82.CrossRefPubMed
40.
Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther. 2016;8:39.CrossRefPubMedPubMedCentral
41.
Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. Biomed Res Int. 2016;2016:3245935.CrossRefPubMedPubMedCentral
42.
Rodrigue KM, Kennedy KM, Devous MD, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387–95.CrossRefPubMedPubMedCentral
43.
Reitz C, Honig L, Vonsattel JP, Tang M-X, Mayeux R. Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry. 2009;80(7):715–21.CrossRefPubMed
44.
Dowling NM, Farias ST, Reed BR, Sonnen JA, Strauss ME, Schneider JA, Bennett DA, Mungas D. Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults. J Int Neuropsychol Soc. 2011;17(4):602–14.CrossRefPubMedPubMedCentral
45.
Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72(4):599–609.CrossRefPubMedPubMedCentral
46.
Mufson EJ, Malek-Ahmadi M, Perez SE, Chen K. Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiol Aging. 2016;37:147–53.CrossRefPubMed
47.
Mufson EJ, Malek-Ahmadi M, Perez SE, Chen K. Braak stage and trajectory of cognitive decline in non-cognitively impaired elders. Neurobiol Aging. 2016;43:101–10.CrossRefPubMedPubMedCentral
48.
Malek-Ahmadi M, Perez SE, Chen K, Mufson EJ. Neuritic and diffuse plaque associations with memory in non-cognitively impaired elderly. J Alzheimers Dis. 2016;53(4):1641–52.CrossRefPubMedPubMedCentral
49.
50.
Jellinger KA, Attems J. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol. 2007;113(2):107–17.CrossRefPubMed
51.
Schwartz M, Serrano G, Beach TG, Tsai A, Malek-Ahmadi M, Jacobson SA, Sue LI, Davis K, Sabbagh MN, Serano G. Neurofibrillary tangle predominant dementia: clinical and pathological description in a case series. J Alzheimers Dis Parkinsonism. 2016;6:204.CrossRef
52.
Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL III, Wisniewski T, Woltjer RL, Yamada M, Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755–66.CrossRefPubMedPubMedCentral
53.
Goldberg R, Gore JM, Barton B, Gurwitz J. Individual and composite study endpoints: separating the wheat from the chaff. Am J Med. 2014;127(5):379–84.CrossRefPubMedPubMedCentral
54.
Kryscio RJ. Secondary prevention trials in AD: the challenge of identifying a meaningful endpoint. J Am Med Assn Neurol. 2014;71(8):947–9.
55.
Ard MC, Raghavan N, Edland SD. Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm Stat. 2015;14(5):418–26.CrossRefPubMedPubMedCentral
56.
Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 2012;123:13–30.CrossRefPubMed
57.
Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS. Alzheimer's disease cooperative study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–91.CrossRefPubMedPubMedCentral
58.
Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potential. J Prev Alz Dis. 2017;4(3):149–56.
59.
Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13(11):1092–9.CrossRefPubMed
60.
Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131–46.CrossRefPubMedPubMedCentral
61.
Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DA, Pontecorvo MJ, For the AV-45 A11 study group. Florbetapir F18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044–51.CrossRefPubMedPubMedCentral
62.
Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016;12(2):110–20.CrossRefPubMed
63.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P, SCarlet RoAD investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther. 2017;9(1):95.CrossRefPubMedPubMedCentral
Metadata
Title
Cognitive composite score association with Alzheimer’s disease plaque and tangle pathology
Authors
Michael Malek-Ahmadi
Kewei Chen
Sylvia E. Perez
Anna He
Elliott J. Mufson
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2018
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-018-0401-z

Other articles of this Issue 1/2018

Alzheimer's Research & Therapy 1/2018 Go to the issue

Research

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Research

Cerebrovascular disease influences functional and structural network connectivity in patients with amnestic mild cognitive impairment and Alzheimer’s disease

Research

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels

Research

Secondary prevention of Alzheimer’s dementia: neuroimaging contributions

Viewpoint

Why could meditation practice help promote mental health and well-being in aging?

Research

Prospective associations between pulse pressure and cognitive performance in Chinese middle-aged and older population across a 5-year study period